Abstract
Background Current predictors of clinical deterioration in patients with heart-failure with reduced ejection fraction (HFrEF) have limited accuracy. We investigated whether stroke volume reserve index (SVRI) would predict 1-year mortality and need for advanced therapies in HFrEF patients.
Methods We retrospectively studied a consecutive series of 104 ambulatory HFrEF patients (59±11 years, 89% men) at our center who underwent cardiopulmonary exercise testing (CPET) from January 2017 to September 2018. The primary outcome was defined as heart-transplantation, urgent left ventricular assist device (LVAD) implantation or death within 1 year of evaluation. SVRI was estimated at rest and at anaerobic threshold (AT) by VO2 (oxygen consumption)/pulse and previously validated estimates of C[a-v]O2 (arteriovenous difference in oxygen content). Multivariate regression selected the optimal predictors from clinical, CPET and right heart catheterization data.
Results Among HFrEF patients studied, 39 (37.5%) deteriorated: 16 required heart-transplantation, 8 required LVADs and 15 died. SVRI 128% or less was the best predictor (OR 6.69, p=0.001), followed by an invasively determined resting cardiac index 2 L/min/m2 or less (OR 3.18, p=0.02), and peak VO2 below the International Society for Heart and Lung Transplantation (ISHLT) cut-off (OR 4.15, p=0.01). A scoring system derived from the SVRI (less than 128%: 2 points), peak VO2 (below the ISHLT cut-off: 1 point), and cardiac index (less than 2 L/min/m2: 1 point) predicted clinical deterioration with a sensitivity of 64% and specificity of 81%.
Conclusions SVRI is a non-invasive measurement that may predict deterioration in HFrEF patients more accurately than currently recommended predictors.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors did not receive any payment or services related to this research project
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data referred to in the manuscript is available and can be obtained by emailing iselevany{at}health.ucsd.edu
